Compare Biogen Inc (BIIB) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Biogen Inc trades at $194.61 (market cap $28.34B), while YieldMax NVDA Option Income Strategy ETF trades at $12.69. The key difference: Biogen Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | NVDY | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $216.63 | $17.96 |
52-Week Low | $122.68 | $12.03 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.43, down 2.51% today, reflecting bearish technical signals with moving averages indicating selling pressure. The fund generates weekly dividends but lacks traditional valuation metrics like P/E or P/S, as it is structured to monetize NVIDIA's volatility through options strategies. Recent news highlights its focus on income generation at the potential cost of capping NVIDIA's upside returns.
The outlook for NVDY hinges on sustained options premium income amid NVIDIA's stock volatility, offering high distribution yields but limiting capital appreciation. Key risks include underperformance versus holding NVIDIA directly, fee drag, and dependency on market conditions for options profitability. Investors seeking income may find value, but growth-oriented investors face significant opportunity cost.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
